NRX101 Glx Biomarker Validation Study (NRX-GLX)
Validation of the Glx Biomarker for Treatment of Moderate Bipolar Depression With NRX-101
Sponsor: NeuroRx, Inc.
Listed as NCT03402152, this PHASE2/PHASE3 trial focuses on Bipolar Depression and Suicidal Ideation and remains completed. Sponsored by NeuroRx, Inc., it has been updated 12 times since 2018, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jul 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Jul 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2018 — Apr 2018 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- NeuroRx, Inc.
- Target Health Inc.
For direct contact, visit the study record on ClinicalTrials.gov .